FDA Grants Regenerative Medication Superior Remedy (RMAT) designation to Autolus’ CAR T cell remedy, obe-cel, for the remedy of grownup B-ALL
Autolus Restricted LONDON, April 25, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical firm creating next-generation programmed T cell therapies, right this moment introduced that the U.S. Meals and Drug Administration (FDA) has granted Regenerative Medication Superior Remedy (RMAT) designation to its lead gene remedy obecabatagene autoleucel (obe-cel), a CD19-directed autologous…